Business Wire (Free subscription) | 01/10/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its
Medical News Today (Free subscription) | 25/09/2008
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that key data on sustained viral response (SVR) rates in both treatment-naïve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens will be presented at the 59th Annual Meeting o
Market Watch (Free subscription) | 24/09/2008
BOSTON (MarketWatch) -- Shares of Vertex Pharmaceuticals rocketed in afternoon trading Wednesday, fueled by the release of positive data for its hepatitis C drug candidate telaprevir. The Cambridge, Mass. biotech group released six abstracts of key data for telaprevir ahead of the annual meeting of the American Association for the Study of Liver Disease, to be held Oct. 31 through Nov. 4 in San Francisco....
Business Wire (Free subscription) | 24/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the
The Boston Business Journal (Free subscription) | 22/09/2008
Vertex Pharmaceuticals Inc., which originally planned to raise $191 million through a public offering, will now raise $220 million.
Business Wire (Free subscription) | 22/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter has exercised in full its option to purchase 1,125,000 shares of
Business Wire (Free subscription) | 19/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
The Boston Business Journal (Free subscription) | 18/09/2008
Vertex Pharmaceuticals Inc. plans to sell 7.5 million shares in a bid to raise more than $191 million, the company announced Thursday.
Market Watch (Free subscription) | 18/09/2008
BOSTON (MarketWatch) -- Vertex Pharmaceuticals said Thursday that it plans to offer 7.5 million of its common shares at $25.50 a share. The biotech group said it expects to raise about $191.3 million in gross proceeds from the offering. Vertex has granted its underwriter the option to purchase up to 1.125 million in additional shares. Market Pulse Stories are Rapid-fire, short news bursts on stocks...
Business Wire (Free subscription) | 18/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an
Business Wire (Free subscription) | 17/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of
Business Wire (Free subscription) | 04/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate
Patent Docs (Free subscription) | 04/09/2008
By Kevin E. Noonan -- Earlier today, Patent Docs participated in a conference call with Jim Greenwood, the President and CEO of the Biotechnology Industry Organization (BIO) and Joshua Boger, Ph.D., Chairman of BIO's Board and President and CEO of Vertex Pharmaceuticals Inc. Mr. Greenwood, who represented Pennsylvania's Eighth District in the U.S. House of Representatives from January 1993 through...
Business Wire (Free subscription) | 29/08/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate
Medical News Today (Free subscription) | 22/08/2008
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the Company has reached agreement with U.S. and E.U.
